Chemclin Diagnostics Co., Ltd. (SHA:688468)
China
· Delayed Price · Currency is CNY 6.98
+0.12 (1.75%)
Apr 30, 2025, 2:45 PM CST
Chemclin Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 436.29 | 445.34 | 465.27 | 470.77 | 418.2 | Upgrade
|
| Revenue Growth (YoY) | -2.03% | -4.28% | -1.17% | 12.57% | -8.02% | Upgrade
|
| Cost of Revenue | - | 110.56 | 121.11 | 119.84 | 117.25 | Upgrade
|
| Gross Profit | 436.29 | 334.78 | 344.16 | 350.94 | 300.95 | Upgrade
|
| Selling, General & Admin | - | 133.41 | 135.17 | 143.23 | 129.03 | Upgrade
|
| Research & Development | - | 65.14 | 68.36 | 66.78 | 54.33 | Upgrade
|
| Other Operating Expenses | 301.54 | 5.13 | 5.49 | 3.66 | 3.22 | Upgrade
|
| Operating Expenses | 301.54 | 203.27 | 209.05 | 213.82 | 186.87 | Upgrade
|
| Operating Income | 134.75 | 131.51 | 135.11 | 137.12 | 114.09 | Upgrade
|
| Interest Expense | - | -0.47 | -0.52 | -0.73 | -0.01 | Upgrade
|
| Interest & Investment Income | - | 22.04 | 25.03 | 18.29 | 13.86 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.08 | 0.4 | -0.13 | -0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.08 | -0.15 | -0.08 | -0.42 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | 137.83 | 153.02 | 159.93 | 154.13 | 127.57 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.14 | -0.62 | -0.64 | -0.34 | Upgrade
|
| Asset Writedown | - | -2.8 | -1.46 | -0.32 | - | Upgrade
|
| Other Unusual Items | - | 15.76 | 19.51 | 9.02 | 8.21 | Upgrade
|
| Pretax Income | 137.83 | 166.12 | 177.37 | 162.19 | 135.44 | Upgrade
|
| Income Tax Expense | 10.83 | 18.75 | 24.74 | 19.43 | 18.42 | Upgrade
|
| Net Income | 126.99 | 147.37 | 152.63 | 142.76 | 117.02 | Upgrade
|
| Net Income to Common | 126.99 | 147.37 | 152.63 | 142.76 | 117.02 | Upgrade
|
| Net Income Growth | -13.83% | -3.44% | 6.91% | 21.99% | -16.77% | Upgrade
|
| Shares Outstanding (Basic) | 397 | 398 | 402 | 386 | 355 | Upgrade
|
| Shares Outstanding (Diluted) | 397 | 398 | 402 | 386 | 355 | Upgrade
|
| Shares Change (YoY) | -0.36% | -0.83% | 4.10% | 8.80% | 76.55% | Upgrade
|
| EPS (Basic) | 0.32 | 0.37 | 0.38 | 0.37 | 0.33 | Upgrade
|
| EPS (Diluted) | 0.32 | 0.37 | 0.38 | 0.37 | 0.33 | Upgrade
|
| EPS Growth | -13.51% | -2.63% | 2.70% | 12.12% | -52.86% | Upgrade
|
| Free Cash Flow | - | -128.32 | 119.28 | 116.31 | 68.65 | Upgrade
|
| Free Cash Flow Per Share | - | -0.32 | 0.30 | 0.30 | 0.19 | Upgrade
|
| Dividend Per Share | - | 0.125 | 0.347 | 0.170 | - | Upgrade
|
| Dividend Growth | - | -63.98% | 104.12% | - | - | Upgrade
|
| Gross Margin | 100.00% | 75.17% | 73.97% | 74.54% | 71.96% | Upgrade
|
| Operating Margin | 30.89% | 29.53% | 29.04% | 29.13% | 27.28% | Upgrade
|
| Profit Margin | 29.11% | 33.09% | 32.80% | 30.32% | 27.98% | Upgrade
|
| Free Cash Flow Margin | - | -28.81% | 25.64% | 24.71% | 16.41% | Upgrade
|
| EBITDA | 171.54 | 168.3 | 175.19 | 179.97 | 156.35 | Upgrade
|
| EBITDA Margin | 39.32% | 37.79% | 37.65% | 38.23% | 37.39% | Upgrade
|
| D&A For EBITDA | 36.79 | 36.79 | 40.08 | 42.84 | 42.26 | Upgrade
|
| EBIT | 134.75 | 131.51 | 135.11 | 137.12 | 114.09 | Upgrade
|
| EBIT Margin | 30.89% | 29.53% | 29.04% | 29.13% | 27.28% | Upgrade
|
| Effective Tax Rate | 7.86% | 11.29% | 13.95% | 11.98% | 13.60% | Upgrade
|
| Revenue as Reported | - | 445.34 | 465.27 | 470.77 | 418.2 | Upgrade
|
| Advertising Expenses | - | 6.63 | 4.1 | 6.76 | 5.87 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.